References
Kersten HM, Roxburgh RH, Child N, Polkinghorne PJ, Frampton C, Danesh-Meyer HV (2014) Epiretinal membrane: a treatable cause of visual disability in myotonic dystrophy type 1. J Neurol 261(1):37–44
Choi SH, Yang HK, Hwang JM, Park KS (2016) Ocular findings of myotonic dystrophy type 1 in the Korean population. Graefes Arch Clin Exp Ophthalmol 254(6):1189–1193
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA et al (1991) Optical coherence tomography. Science 254(5035):1178–1181
Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293(5531):864–867
Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, Peltonen L, Krahe R, Udd B (2011) Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 19(7):776–782
Finsterer J (2002) Myotonic dystrophy type 2. Eur J Neurol 9(5):441–447
Fraser-Bell S, Guzowski M, Rochtchina E, Wang JJ, Mitchell P (2003) Five-year cumulative incidence and progression of epiretinal membranes: the Blue Mountains Eye Study. Ophthalmology 110(1):34–40
Watanabe A, Arimoto S, Nishi O (2009) Correlation between metamorphopsia and epiretinal membrane optical coherence tomography findings. Ophthalmology 116(9):1788–1793
Turner C, Hilton-Jones D (2010) The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry 81(4):358–367
Hayasaka S, Kiyosawa M, Katsumata S, Honda M, Takase S, Mizuno K (1984) Ciliary and retinal changes in myotonic dystrophy. Arch Ophthalmol 102(1):88–93
Kimizuka Y, Kiyosawa M, Tamai M, Takase S (1993) Retinal changes in myotonic dystrophy: clinical and follow-up evaluation. Retina 13(2):129–135
Rosa N, Lanza M, Borrelli M, De Bernardo M, Palladino A, Di Gregorio MG, Pascotto F, Politano L (2011) Low intraocular pressure resulting from ciliary body detachment in patients with myotonic dystrophy. Ophthalmology 118(2):260–264
Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP (2003) Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60(4):657–664
Ghazi-Nouri SMS, Tranos PG, Rubin GS, Adams ZC, Charteris DG (2006) Visual function and quality of life following vitrectomy and epiretinal membrane peel surgery. Br J Ophthalmol 90(5):559–562
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethical standards
This study has been approved by the appropriate ethics committees (Northern X (NTX/11/EXP/022) and ADHB Ethics Committees (A+5185)) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants gave their informed consent prior to participation in this study.
Rights and permissions
About this article
Cite this article
Kersten, H.M., Danesh-Meyer, H.V. & Roxburgh, R.H. Ophthalmic findings in myotonic dystrophy type 2: a case series. J Neurol 263, 2552–2554 (2016). https://doi.org/10.1007/s00415-016-8325-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8325-7